What does the current price mean for Embody Semaglutide?

The canonical catalog records $79 a month, continuing for Compounded semaglutide injection, checked 22 August 2026. The amount should be read with any introduction, prepayment, or commitment shown in the same offer record. It is a dated published commercial fact, not a promise that every checkout configuration, future renewal, or product change will cost the same amount.

What is included in the Embody figure?

The canonical Embody offer marks medication as included for Semaglutide. That field does not automatically include labs, every consultation, supplies, faster shipping, dose-related price changes, or a future refill. Confirm those items and the complete charge in the selected checkout before treating the figure as all-inclusive.

Which product is this for Embody Semaglutide?

This record is limited to Compounded semaglutide injection in Weekly subcutaneous injection format. It does not transfer price, regulatory status, evidence, convenience, dosing, pharmacy, or fulfillment claims to another Semaglutide formulation or to a related product. Compare route and product identity before comparing the price because similar medication names can still describe materially different offers.

How is state access handled for Embody Semaglutide?

The current record lists Louisiana as restricted for this vertical. Confirm eligibility directly because provider coverage can change. The state record is only one access field. Embody must also confirm clinician licensure, product eligibility, and pharmacy fulfillment for the specific Semaglutide prescription. Completing an intake does not guarantee approval, dispensing, or a particular outcome.

Where should it be compared for Embody Semaglutide?

Use the canonical Semaglutide program comparison. It reads current provider and price data from the registry and preserves the compounded-semaglutide treatment route. Compare Embody only with offers that disclose the same price components, medication inclusion, commitment, and format; otherwise explain why the rows are not directly equivalent.

Provider treatment guide · checked 22 August 2026

Embody Semaglutide

Published by Telehealth LedgerSource checked 22 August 2026Editorial policy

Embody lists Compounded semaglutide injection at $79 a month, continuing. Medication is included in that catalog price. Readers considering Embody specifically for compounded semaglutide who want its current offer identity and pricing basis kept separate from provider-level marketing. The commercial terms were checked 22 August 2026; state access, clinician approval, dispensing details, and personal suitability remain separate questions.

Visit Embody Read the full review

Embody Semaglutide treatment illustration

$79a month, continuing

Includedmedication in catalog price

Weekly subcutaneous injectioncataloged format

22 August 2026commercial terms checked

1 listed restrictionstate-access record

Start with the exact decision: Embody Semaglutide

Decide whether Embody's compounded semaglutide catalog offer fits the reader's preferred format and commercial terms before comparing it with Embody's tirzepatide option or the full semaglutide field.

Readers considering Embody specifically for compounded semaglutide who want its current offer identity and pricing basis kept separate from provider-level marketing. The useful question is whether Compounded semaglutide injection, its weekly subcutaneous injection route, and the recorded plan structure match the offer the reader intended to evaluate.

Read the price on its real basis: Embody

Embody's canonical offer lists Compounded semaglutide injection at $79 a month, continuing. The number is computed from the same registry fields used by the treatment comparison, not copied into this draft as a fixed editorial amount. That connection matters because a future catalog correction can update the displayed commercial fact without leaving this guide on a stale, contradictory figure.

The canonical offer marks medication as included in the displayed price. It does not verify that labs, every consultation, supplies, expedited shipping, or future dose changes are included unless the source says so. Those items remain checkout questions. For Embody Semaglutide, read inclusion as one field in the offer record, not as proof that every service surrounding the prescription is free. The dated source establishes the advertised basis; it does not independently audit the final checkout, dispensing event, or quality of care.

Keep product and route together: Compounded semaglutide injection

Compounded semaglutide injection is cataloged as a compounded product in Weekly subcutaneous injection format. FDA states that compounded drugs are not FDA-approved and do not receive the same premarket review as approved drug products. Ask for the exact formulation and dispensing pharmacy before purchase. That status is central to this Embody guide because a related medication name does not make branded, compounded, oral, nasal, and injectable products interchangeable.

Weekly subcutaneous injection is the exact format attached to Embody's offer, while the canonical owner describes this comparison unit as Compounded semaglutide injection. Route matters for product identification, fulfillment, source selection, and a fair price comparison. This draft does not supply dose instructions, route conversions, or a claim that another formulation would have the same evidence, safety profile, convenience, or outcome.

Separate monthly cost from commitment: Embody Semaglutide

The catalog has both a continuing option at $79 a month, continuing and a prepaid option at $69 a month, paying $828 for 12 months up front. Those are different commitments. Compare the total charged today, the renewal path, and the cancellation deadline rather than treating the lowest monthly equivalent as month to month. This is why Telehealth Ledger keeps introductory, recurring, upfront, effective-monthly, and commitment fields separate for Embody's Semaglutide offer. A monthly equivalent can be useful, but only when the required payment and term remain visible beside it.

The Embody source for this edge was checked on 22 August 2026. Before paying for Semaglutide, compare the amount charged today with the amount charged later, the number of months purchased, the renewal date, the cancellation window, and the refund boundary after clinical or pharmacy processing. A current catalog price cannot safely answer those policy questions unless the cited provider evidence does.

Know who operates and fulfills the program: Embody

Modern Metabolic Medicine, Inc. is recorded in the Embody dossier as administrator. Administrative operator named in the terms. These entities can perform different jobs, so the consumer-facing brand should not automatically be described as the clinician or dispensing pharmacy for Semaglutide.

Cancellation deadline: Embody requires notice at least 72 hours before billing. The dossier also preserves this boundary for Embody's Semaglutide decision: Affiliate landing compresses prepay prices: The $69 and $119 headlines are twelve-month effective rates; current month-to-month prices are higher. Carry that dated limitation into checkout instead of assuming a catalog price settles operations, fulfillment, or eligibility.

Verify state access before intake: Semaglutide

The canonical provider record lists Louisiana as restricted for weight-loss programs. That list is a dated catalog fact, not proof of eligibility everywhere else. Confirm the current state rule before intake. The Semaglutide access check belongs near the price because a low published figure has little decision value when Embody cannot serve the reader's state or the selected product cannot be fulfilled there.

For Embody Semaglutide, the consumer brand, administrative platform, clinical group, and dispensing pharmacy can be different entities. A provider page may describe a national service while licensure, product rules, and pharmacy coverage narrow actual fulfillment. Ask which clinician entity would review the intake and which licensed pharmacy would dispense this exact product in the reader's state before treating access as settled.

Build a like-for-like shortlist: Semaglutide

The linked Semaglutide owner is the right place to rank Embody beside other cataloged offers. Use the same fields for every row: continuing price, introductory period, required prepayment, medication inclusion, product type, delivery format, verification date, and state evidence. If two offers use different routes or one price excludes medication, a simple lowest-number verdict would not be a like-for-like conclusion.

From this Embody guide, the comparison link resolves to the canonical Semaglutide program owner, and the provider action uses the catalog's treatment-specific destination when one exists. Otherwise it uses the matching weight-loss destination. That routing keeps the reader in the correct treatment lane and avoids sending a Semaglutide decision to an unrelated offer.

The practical verdict: Embody Semaglutide

Embody earns consideration for this narrow comparison because the catalog supplies a disclosed Semaglutide price, identifies Compounded semaglutide injection, and records medication inclusion. It does not earn a clinical recommendation from those commercial facts.

Readers considering Embody specifically for compounded semaglutide who want its current offer identity and pricing basis kept separate from provider-level marketing. Before proceeding, reopen the dated source, compare the canonical Semaglutide owner, and save the exact checkout terms that govern the selected plan.

Common questions

Embody Semaglutide FAQ

What does the current price mean for Embody Semaglutide?: The canonical catalog records $79 a month, continuing for Compounded semaglutide injection, checked 22 August 2026. The amount should be read with any introduction, prepayment, or commitment shown in the same offer record. It is a dated published commercial fact, not a promise that every checkout configuration, future renewal, or product change will cost the same amount.
What is included in the Embody figure?: The canonical Embody offer marks medication as included for Semaglutide. That field does not automatically include labs, every consultation, supplies, faster shipping, dose-related price changes, or a future refill. Confirm those items and the complete charge in the selected checkout before treating the figure as all-inclusive.
Which product is this for Embody Semaglutide?: This record is limited to Compounded semaglutide injection in Weekly subcutaneous injection format. It does not transfer price, regulatory status, evidence, convenience, dosing, pharmacy, or fulfillment claims to another Semaglutide formulation or to a related product. Compare route and product identity before comparing the price because similar medication names can still describe materially different offers.
How is state access handled for Embody Semaglutide?: The current record lists Louisiana as restricted for this vertical. Confirm eligibility directly because provider coverage can change. The state record is only one access field. Embody must also confirm clinician licensure, product eligibility, and pharmacy fulfillment for the specific Semaglutide prescription. Completing an intake does not guarantee approval, dispensing, or a particular outcome.
Where should it be compared for Embody Semaglutide?: Use the canonical Semaglutide program comparison. It reads current provider and price data from the registry and preserves the compounded-semaglutide treatment route. Compare Embody only with offers that disclose the same price components, medication inclusion, commitment, and format; otherwise explain why the rows are not directly equivalent.

Sources and method

Telehealth Ledger checked provider pages, plan terms, and independent context on 22 August 2026. This page compares published commercial terms. It is not a rating, medical advice, or a guarantee that a clinician will prescribe treatment.